AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM
I'm LongbridgeAI, I can summarize articles.AC Immune shareholders approved the 2025 financial statements, compensation report, and governance slate at its June 11 AGM. Key approvals included a capital band for flexible share capital adjustments through 2031 and expanded conditional share capital for employee benefits. Despite a CHF 67.6 million net loss, management highlighted CHF 74.8 million in cash reserves expected to fund operations into late 2027.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
AC Immune SA ( (ACIU) ) has shared an announcement.
On June 11, 2026, AC Immune SA held its Annual General Meeting, where shareholders approved the company’s 2025 IFRS consolidated and statutory financial statements and endorsed the 2025 compensation report, despite the year’s CHF 67.6 million net loss bringing accumulated losses to CHF 424.4 million. Investors also discharged the Board and executive management for 2025, re-elected all standing directors, committee members, the statutory auditor and independent proxy, and backed maximum compensation caps for the Board and executives for the periods through 2027.
Strategically, shareholders approved amendments to the Articles of Association introducing a capital band that empowers the Board to flexibly increase or decrease share capital within set limits through June 2031, and expanded the conditional share capital for employee benefit plans, reinforcing AC Immune’s financial and equity toolkit to support its long-term drug development programs. Management highlighted that post-2025 restructuring and cost savings, cash reserves of CHF 74.8 million as of March 31, 2026 are expected to fund operations into the fourth quarter of 2027, underlining both the company’s capital needs and its efforts to extend runway while advancing clinical-stage assets in neurodegenerative disease.
The most recent analyst rating on (ACIU) stock is a Buy
with a $12.00 price target.
To see the full list of analyst forecasts on AC Immune SA stock,
see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
The score is driven primarily by weak financial performance (persistent losses, 2025 revenue decline, and a return to heavy cash burn despite low debt) and bearish technical conditions (below key moving averages with negative MACD). Valuation provides limited offset because the negative P/E is not informative and no dividend yield is available.
To see Spark’s full report on ACIU stock,
click here.
More about AC Immune SA
AC Immune SA is a Lausanne, Switzerland-based biopharmaceutical company listed on Nasdaq under the ticker ACIU, focused on precision medicine for neurodegenerative diseases. Using proprietary active immunotherapy and small-molecule platforms, the company develops targeted therapeutics and diagnostics against key pathological proteins such as amyloid beta, Tau and alpha-synuclein, with a pipeline aimed at early intervention and prevention.
Average Trading Volume: 274,290
Technical Sentiment Signal: Strong Sell
Current Market Cap: $215.8M
Find detailed analytics on ACIU stock on TipRanks’ Stock Analysis page.